Company Description
Seres Therapeutics, Inc., a clinical-stage company, develop microbiome therapeutics to treat the modulation of the colonic microbiome.
The company develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.
The company’s product candidate is VOWST, the first FDA-approved orally administered microbiome therapeutic.
Its product pipeline also includes SER-155, an investigational, oral, live biotherapeutic designed to decolonize gastrointestinal, or GI, pathogens, improve epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, or BSIs, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation, or allo-HSCT.
In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis.
Further, it develops SER-147, an investigational live biotherapeutic designed to prevent bacterial bloodstream and spontaneous bacterial peritonitis, or SBP, infections in patients with metabolic disease, including clinical liver disease.
The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015.
Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2010 |
| IPO Date | Jun 26, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 103 |
| CEO | Eric Shaff |
Contact Details
Address: 101 Cambridgepark Drive Cambridge, Massachusetts 02140 United States | |
| Phone | 617 945 9626 |
| Website | serestherapeutics.com |
Stock Details
| Ticker Symbol | MCRB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001609809 |
| CUSIP Number | 81750R201 |
| ISIN Number | US81750R2013 |
| Employer ID | 27-4326290 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Eric D. Shaff M.B.A. | President, Chief Executive Officer and Director |
| Thomas J. DesRosier Esq., J.D. | Chief Legal Officer, Executive Vice President and Secretary |
| Dr. Matthew R. Henn Ph.D. | Executive Vice President and Chief Scientific Officer |
| Dr. Teresa L. Young Ph.D., R.Ph. | Executive Vice President and Chief Commercial and Strategy Officer |
| Chris McChalicher | Senior Vice President of Manufacturing, Quality, and Process Development |
| Dr. Dennis M. Walling M.D. | Senior Vice President of Clinical Development and Head of Clinical Research |
| Ann Kurowski | Senior Vice President of Regulatory Affairs |
| Kelly Brady | Senior Vice President of Clinical Development |
| Caroline Holda | Assistant General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 7, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 7, 2025 | 10-Q | Quarterly Report |
| May 7, 2025 | 8-K | Current Report |
| Apr 22, 2025 | 8-K | Current Report |
| Apr 14, 2025 | 8-K | Current Report |
| Apr 4, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 13, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 13, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 13, 2025 | 10-K | Annual Report |
| Mar 13, 2025 | 8-K | Current Report |